Literature DB >> 16796389

Monoclonal antibody form and function: manufacturing the right antibodies for treating drug abuse.

Eric Peterson1, S Michael Owens, Ralph L Henry.   

Abstract

Drug abuse continues to be a major national and worldwide problem, and effective treatment strategies are badly needed. Antibodies are promising therapies for the treatment of medical problems caused by drug abuse, with several candidates in preclinical and early clinical trials. Monoclonal antibodies can be designed that have customized affinity and specificity against drugs of abuse, and because antibodies can be designed in various forms, in vivo pharmacokinetic characteristics can be tailored to suit specific clinical applications (eg, long-acting for relapse prevention, or short-acting for overdose). Passive immunization with antibodies against drugs of abuse has several advantages over active immunization, but because large doses of monoclonal antibodies may be needed for each patient, efficient antibody production technology is essential. In this minireview we discuss some of the antibody forms that may be effective clinical treatments for drug abuse, as well as several current and emerging production systems that could bridge the gap from discovery to patient use.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16796389      PMCID: PMC3231570          DOI: 10.1007/bf02854909

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  29 in total

1.  High level production of functional antibody Fab fragments in an oxidizing bacterial cytoplasm.

Authors:  Miro Venturi; Claudia Seifert; Carola Hunte
Journal:  J Mol Biol       Date:  2002-01-04       Impact factor: 5.469

Review 2.  Transcytosis and catabolism of antibody.

Authors:  Victor Ghetie; E Sally Ward
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

Review 3.  The production of recombinant pharmaceutical proteins in plants.

Authors:  Julian K-C Ma; Pascal M W Drake; Paul Christou
Journal:  Nat Rev Genet       Date:  2003-10       Impact factor: 53.242

Review 4.  Magnifection--a new platform for expressing recombinant vaccines in plants.

Authors:  Y Gleba; V Klimyuk; S Marillonnet
Journal:  Vaccine       Date:  2005-03-18       Impact factor: 3.641

Review 5.  Finally! The Brambell receptor (FcRB). Mediator of transmission of immunity and protection from catabolism for IgG.

Authors:  R P Junghans
Journal:  Immunol Res       Date:  1997-02       Impact factor: 2.829

6.  Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies.

Authors:  Laura C Simmons; Dorothea Reilly; Laura Klimowski; T Shantha Raju; Gloria Meng; Paul Sims; Kyu Hong; Robert L Shields; Lisa A Damico; Patricia Rancatore; Daniel G Yansura
Journal:  J Immunol Methods       Date:  2002-05-01       Impact factor: 2.303

7.  Systemic Agrobacterium tumefaciens-mediated transfection of viral replicons for efficient transient expression in plants.

Authors:  Sylvestre Marillonnet; Carola Thoeringer; Romy Kandzia; Victor Klimyuk; Yuri Gleba
Journal:  Nat Biotechnol       Date:  2005-05-08       Impact factor: 54.908

8.  Serum-free large-scale transient transfection of CHO cells.

Authors:  Madiha Derouazi; Philippe Girard; Frédéric Van Tilborgh; Keyvan Iglesias; Natalie Muller; Martin Bertschinger; Florian M Wurm
Journal:  Biotechnol Bioeng       Date:  2004-08-20       Impact factor: 4.530

Review 9.  Protein disulfide bond formation in prokaryotes.

Authors:  Hiroshi Kadokura; Federico Katzen; Jon Beckwith
Journal:  Annu Rev Biochem       Date:  2003-01-09       Impact factor: 23.643

10.  The production of antibody fragments and antibody fusion proteins by yeasts and filamentous fungi.

Authors:  Vivi Joosten; Christien Lokman; Cees AMJJ Van Den Hondel; Peter J Punt
Journal:  Microb Cell Fact       Date:  2003-01-30       Impact factor: 5.328

View more
  13 in total

Review 1.  Pharmacokinetic strategies for treatment of drug overdose and addiction.

Authors:  David A Gorelick
Journal:  Future Med Chem       Date:  2012-02       Impact factor: 3.808

2.  Rapid high-yield expression of full-size IgG antibodies in plants coinfected with noncompeting viral vectors.

Authors:  Anatoli Giritch; Sylvestre Marillonnet; Carola Engler; Gerben van Eldik; Johan Botterman; Victor Klimyuk; Yuri Gleba
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-14       Impact factor: 11.205

3.  Delivery of an miR155 inhibitor by anti-CD20 single-chain antibody into B cells reduces the acetylcholine receptor-specific autoantibodies and ameliorates experimental autoimmune myasthenia gravis.

Authors:  Y-Z Wang; F-F Tian; M Yan; J-M Zhang; Q Liu; J-Y Lu; W-B Zhou; H Yang; J Li
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

4.  Carboxylate-dependent gelation of a monoclonal antibody.

Authors:  Osigwe Esue; Sonoko Kanai; Jun Liu; Thomas W Patapoff; Steven J Shire
Journal:  Pharm Res       Date:  2009-11       Impact factor: 4.200

Review 5.  Customizing monoclonal antibodies for the treatment of methamphetamine abuse: current and future applications.

Authors:  Eric C Peterson; W Brooks Gentry; S Michael Owens
Journal:  Adv Pharmacol       Date:  2014

6.  Designing immunotherapies to thwart drug abuse.

Authors:  Eric C Peterson; S Michael Owens
Journal:  Mol Interv       Date:  2009-06

7.  PEGylation of a High-Affinity Anti-(+)Methamphetamine Single Chain Antibody Fragment Extends Functional Half-Life by Reducing Clearance.

Authors:  Emily E Reichard; Nisha Nanaware-Kharade; Guillermo A Gonzalez; Shraddha Thakkar; S Michael Owens; Eric C Peterson
Journal:  Pharm Res       Date:  2016-09-12       Impact factor: 4.200

8.  Antifouling surface layers for improved signal-to-noise of particle-based immunoassays.

Authors:  Annie Chen; Darby Kozak; Bronwyn J Battersby; Robin M Forrest; Nathalie Scholler; Nicole Urban; Matt Trau
Journal:  Langmuir       Date:  2009-12-01       Impact factor: 3.882

9.  Cloning and expression of an anti-LDL(-) single-chain variable fragment, and its inhibitory effect on experimental atherosclerosis.

Authors:  Soraya M Kazuma; Marcela F Cavalcante; Andréia E R Telles; Andrea Queiroz Maranhão; Dulcineia S P Abdalla
Journal:  MAbs       Date:  2013-07-25       Impact factor: 5.857

10.  Antibody degradation in tobacco plants: a predominantly apoplastic process.

Authors:  Verena K Hehle; Matthew J Paul; Pascal M Drake; Julian K C Ma; Craig J van Dolleweerd
Journal:  BMC Biotechnol       Date:  2011-12-30       Impact factor: 2.563

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.